
DENTSPLY SIRONA (XRAY) Stock Forecast & Price Target
DENTSPLY SIRONA (XRAY) Analyst Ratings
Bulls say
Dentsply Sirona's recent performance indicates solid revenue growth, evidenced by a 2.8% increase in reported sales in Europe and 1.8% growth organically, suggesting the company's resilience and potential for sustained momentum. Additionally, revenues from Wellspect Healthcare reached $81 million, reflecting an impressive 8.6% reported increase and 6.7% organic growth, further reinforcing the overall positive financial trajectory. The combination of expected mid-single-digit revenue growth, potential market share gains in clear aligners, and improving margins supports a favorable outlook for Dentsply Sirona's stock.
Bears say
Dentsply Sirona's adjusted earnings per share (EPS) of $0.26 significantly underperformed the expected $0.43, largely due to lower-than-anticipated revenue, gross margin declines, and higher operating expenses. The revenue from the connected technology solutions segment declined by 8.3%, compounded by a $62 million loss linked to the Byte shutdown, contributing to a $0.24 negative impact on adjusted EPS. Additionally, with increased selling, general, and administrative expenses, coupled with a gross margin fall to 52.7%, the company's overall profitability and financial outlook appear increasingly challenging.
This aggregate rating is based on analysts' research of DENTSPLY SIRONA and is not a guaranteed prediction by Public.com or investment advice.
DENTSPLY SIRONA (XRAY) Analyst Forecast & Price Prediction
Start investing in DENTSPLY SIRONA (XRAY)
Order type
Buy in
Order amount
Est. shares
0 shares